Evidence
Zhonghua Gan Zang Bing Za Zhi. 2023 Aug 20;31(8):793-797. doi: 10.3760/cma.j.cn501113-20230801-00026.
ABSTRACT
Fatty liver disease has undergone a major name change, with metabolic dysfunction-associated fatty liver disease (MASLD) replacing nonalcoholic fatty liver disease. The definition of MASLD no longer requires the exclusion of other co-existing liver diseases but instead associates hepatic steatosis with overweight/obesity, type 2 diabetes mellitus, or metabolic disorders and clearly defines the amount of alcohol consumption. The new definition also introduces the concepts of metabolic-related alcoholic liver disease and cryptogenic fatty liver disease. These changes will bring new challenges and opportunities for the design of clinical trials of fatty liver disease drugs and the selection of target populations.
PMID:37723059 | DOI:10.3760/cma.j.cn501113-20230801-00026
Estimated reading time: 2 minute(s)
Latest: Psychiatryai.com #RAISR4D
Cool Evidence: Engaging Young People and Students in Real-World Evidence
Real-Time Evidence Search [Psychiatry]
AI Research
Fatty liver disease’s renaming impacts on drug clinical trials
🌐 90 Days
VR Related Evidence Matrix
- Clinical status and challenges of new drugs for metabolic dysfunction-associated fatty liver disease
- Research progress in the regulation of pathogenesis and the transformation of chronic liver disease by short-chain fatty acids
- Analysis of non-alcoholic fatty liver disease differences from metabolic dysfunction-associated fatty liver disease based on clinical features
- Epidemiology, screening, and Co-management of type 2 diabetes mellitus and Metabolic-dysfunction associated steatotic liver disease
- Research progress on the mechanism of action of heme oxygenase-1 regulating ferroptosis in non-alcoholic fatty liver disease
- Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics
- Impact of the diagnosis of metabolic dysfunction-associated fatty liver disease and non-alcoholic fatty liver disease in patients undergoing liver transplantation for hepatocellular carcinoma
- MAFLD as part of systemic metabolic dysregulation
- MAFLD as part of systemic metabolic dysregulation
- Increased Risk of Colorectal Adenomas with Metabolic-Associated Fatty Liver Disease Components
- Galectin-3 and Severity of Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease
- Spatial genomics: mapping human steatotic liver disease
- Incretin-based investigational therapies for the treatment of MASLD/MASH
- Targeting metabolic-associated fatty liver disease in diabetic kidney disease: A call to action
- Interactions between the metabolic syndrome and alcohol consumption increases the risk of liver disease
- Inflammatory liver diseases and susceptibility to sepsis
- Interplay between metabolic dysfunction-associated fatty liver disease and renal function: An intriguing pediatric perspective
- Intestinal Barrier Dysfunction and Gut Microbiota in Non-Alcoholic Fatty Liver Disease: Assessment, Mechanisms, and Therapeutic Considerations
- The gut-liver axis in fatty liver disease: role played by natural products
- The Global Epidemic of Metabolic Fatty Liver Disease
- The double roles of T cell-mediated immune response in the progression of MASLD
- Occult liver disease: a multinational perspective
- Prognostic value of metabolic dysfunction-associated steatotic liver disease over coronary computed tomography angiography findings: comparison with no-alcoholic fatty liver disease
- Coronary artery disease as a risk factor for metabolic dysfunction-associated steatotic liver disease and liver fibrosis
- Increasing the efficiency of hypolipidemic therapy with the combined use of quercetin in patients with non-alcoholic fatty liver disease on the background of the metabolic syndrome
- Metabolic Muddle. MASLD and MASH on the Horizon
- Changes in the terminology and diagnostic criteria of non-alcoholic fatty liver disease: Implications and opportunities
- Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD)
- Research progress on pyroptosis in liver diseases
- Associations of dietary sugars with liver stiffness in Latino adolescents with obesity differ on PNPLA3 and liver disease severity
- THE GLOBAL EPIDEMIOLOGY OF NON-ALCOHOLIC FATTY LIVER DISEASE AND NON-ALCOHOLIC STEATOHEPATITIS AMONG PATIENTS WITH TYPE 2 DIABETES
- COVID-19 in Individuals with Chronic Liver Diseases
- Muscle strength and non-alcoholic fatty liver disease/metabolic-associated fatty liver disease
- The fatty acid omega hydroxylase genes (CYP4 family) in the progression of metabolic dysfunction-associated steatotic liver disease (MASLD): An RNA sequence database analysis and review
- Metabolic-Associated Steatotic Liver Disease (MASLD): A New Term for a More Appropriate Therapy in Pediatrics?
- Alcohol Drinking Impacts on Adiposity and Steatotic Liver Disease: Concurrent Effects on Metabolic Pathways and Cardiovascular Risks
- Update in lean metabolic dysfunction-associated steatotic liver disease
- Update in lean metabolic dysfunction-associated steatotic liver disease
- A Review: Cytochrome P450 in Alcoholic and Non-Alcoholic Fatty Liver Disease
- Hepatic extracellular ATP/adenosine dynamics in zebrafish models of alcoholic and metabolic steatotic liver disease
- Glycyrrhizin and the Related Preparations: An Inspiring Resource for the Treatment of Liver Diseases
- The effects of replacing ghee with rapeseed oil on liver steatosis and enzymes, lipid profile, insulin resistance, and anthropometric measurements in patients with non-alcoholic fatty liver disease: A randomized controlled clinical trial
- Role of prostaglandin E2 and its receptors in chronic liver disease
- 3D microscaffolds with triple-marker sensitive nanoprobes for studying fatty liver disease in vitro
- Clinicopathological features of Sjogren's syndrome complicated with liver injury
- Patients with Celiac Disease Have High Prevalence of Fatty Liver and Metabolic Syndrome
- Anthocyanin: A Potential Phytochemical Candidate for the Amelioration of Non-Alcoholic Fatty Liver Disease
- Effects of silymarin use on liver enzymes and metabolic factors in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis
- Mass spectrometry imaging-based metabolomics highlights spatial metabolic alterations in three types of liver injuries
- Spleen volume is independently associated with non-alcoholic fatty liver disease, liver volume and liver fibrosis
- SHMT2 reduces fatty liver but is necessary for liver inflammation and fibrosis in mice
- SHMT2 reduces fatty liver but is necessary for liver inflammation and fibrosis in mice
- Role of Angiotensin II in Non-Alcoholic Steatosis Development
- Anxiety and depression in metabolic-associated steatotic liver disease: relation with socio-demographic features and liver disease severity
- Non-invasive tools for liver steatosis and steatohepatitis predict incidence of diabetes, cardiovascular disease and mortality 20 years later: The ATTICA cohort study (2002-2022)
- Prevalence of at-risk MASH, MetALD and alcohol-associated steatotic liver disease in the general population
- Puerarin protects the fatty liver from ischemia-reperfusion injury by regulating the PI3K/AKT signaling pathway
- Regulatory pathways and therapeutic potential of PDE4 in liver pathophysiology
- The Influence of Emodin Succinyl Ethyl Ester on Non-Alcoholic Steatohepatitis Induced by a Diet High in Fructose, Cholesterol, and Fat in Mice
- Role of the angiopoietin-like protein family in the progression of NAFLD
- Interaction between fatty acid oxidation and ethanol metabolism in liver
- Kaempferol efficacy in metabolic diseases: Molecular mechanisms of action in diabetes mellitus, obesity, non-alcoholic fatty liver disease, steatohepatitis, and atherosclerosis
- Predictors for liver fibrosis in non-alcoholic patients with psoriatic diseases: A multicenter cross sectional-study
- Predictors for liver fibrosis in non-alcoholic patients with psoriatic diseases: A multicenter cross sectional-study
Evidence Blueprint
Fatty liver disease’s renaming impacts on drug clinical trials
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
Fatty liver disease’s renaming impacts on drug clinical trials
🌐 365 Days
VR Related Evidence Matrix
- Effect of the nomenclature of non-alcoholic fatty liver disease on diagnosis and treatment of fatty liver disease concomitant with other liver diseases
- Clinical status and challenges of new drugs for metabolic dysfunction-associated fatty liver disease
- Research progress on the histological scoring system for nonalcoholic fatty liver disease
- Research progress in the regulation of pathogenesis and the transformation of chronic liver disease by short-chain fatty acids
- Analysis of non-alcoholic fatty liver disease differences from metabolic dysfunction-associated fatty liver disease based on clinical features
- Metabolic study of iron deposition based on magnetic resonance in patients with nonalcoholic fatty liver disease
- Macrophage heterogeneity role in NAFLD and NASH disease progression
- Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease
- Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity
- Epidemiology, screening, and Co-management of type 2 diabetes mellitus and Metabolic-dysfunction associated steatotic liver disease
- Liver fibrosis screening, evaluation pathway, and management in patients with fatty liver
- Metabolic dysfunction: The silenced connection with fatty liver disease
- Research progress on the mechanism of action of heme oxygenase-1 regulating ferroptosis in non-alcoholic fatty liver disease
- From metabolic dysfunction-associated fatty liver disease to metabolic dysfunction-associated steatotic liver disease: Controversy and consensus
- Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics
- Metabolic Dysfunction-Associated Steatotic Liver Disease: A State-of-the-Art Review
- Frontiers of Collaboration between Primary Care and Specialists in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review
- Improvement situation on indexes of the zebrafish disease model of non-alcoholic fatty liver disease with FGF21 analogues
- Impact of the diagnosis of metabolic dysfunction-associated fatty liver disease and non-alcoholic fatty liver disease in patients undergoing liver transplantation for hepatocellular carcinoma
- Epidemiological characteristics of inpatients with liver failure at the Beijing You'an Hospital from 2012 to 2021
- Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease
- Corrected and republished from: Metabolic associated liver disease
- Research progress of celastrol on the prevention and treatment of metabolic associated fatty liver disease
- MASLD: a systemic metabolic disorder with cardiovascular and malignant complications
- MAFLD as part of systemic metabolic dysregulation
- MAFLD as part of systemic metabolic dysregulation
- Metabolism-related signalling pathways involved in the pathogenesis and development of metabolic dysfunction-associated steatotic liver disease
- Increased Risk of Colorectal Adenomas with Metabolic-Associated Fatty Liver Disease Components
- Hepatic Fibrosis and Cancer: The Silent Threats of Metabolic Syndrome
- Screening, Diagnosis, and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD): Application of Society Guidelines to Clinical Practice
- Diabetes and fatty liver: Involvement of incretin and its benefit for fatty liver management
- Diabetes Mellitus among Patients with Non-alcoholic Fatty Liver Disease Visiting the Outpatient Department of Internal Medicine in a Tertiary Care Centre
- Liver and atherosclerotic risks of patients with cryptogenic steatotic liver disease
- Nonalcoholic Fatty Liver Disease and Continuous Metabolic Syndrome in Adolescents with Overweight/Obesity
- Mitochondrial Quality Control: Its Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
- Galectin-3 and Severity of Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease
- Spatial genomics: mapping human steatotic liver disease
- Incretin-based investigational therapies for the treatment of MASLD/MASH
- Mortality in metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study
- Metabolic dysfunction-associated steatotic liver disease (MASLD) definition is better than MAFLD criteria for lean patients with non-alcoholic fatty liver disease (NAFLD)
- Targeting metabolic-associated fatty liver disease in diabetic kidney disease: A call to action
- Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease
- Metabolic dysfunction-associated fatty liver disease in people living with HIV
- Interactions between the metabolic syndrome and alcohol consumption increases the risk of liver disease
- Chronic liver disease and management with silymarin: an introductory review of a clinical case collection
- Inflammatory liver diseases and susceptibility to sepsis
- Hormone action and liver disease, a complex interplay
- Association of metabolic-dysfunction associated steatotic liver disease with polycystic ovary syndrome
- A multi-society Delphi consensus statement on new fatty liver disease nomenclature
- SGLT-2 Inhibitors for Non-Alcoholic Fatty Liver Disease: A Review
- The Prothrombotic Tendency of Metabolic-Associated Fatty Liver Disease
- What are the common downstream molecular events between alcoholic and nonalcoholic fatty liver?
- What are the common downstream molecular events between alcoholic and nonalcoholic fatty liver?
- Therapeutic management of metabolic dysfunction associated steatotic liver disease
- Ultrasonographic findings of metabolic dysfunction-associated fatty liver disease: A comparative study with non-alcoholic fatty liver disease and clinical characteristics
- Fatty liver and celiac disease: Why worry?
- The role of Sirtuin 2 in liver - An extensive and complex biological process
- Interplay between metabolic dysfunction-associated fatty liver disease and renal function: An intriguing pediatric perspective
- Breaking new ground: MASLD vs. MAFLD-which holds the key for risk stratification?
- Intestinal Barrier Dysfunction and Gut Microbiota in Non-Alcoholic Fatty Liver Disease: Assessment, Mechanisms, and Therapeutic Considerations
- The gut-liver axis in fatty liver disease: role played by natural products
- Metabolic dysfunction-associated steatotic liver disease: Where does non-alcoholic fatty liver disease in liver transplant recipients fit in this new definition?
- Metabolic disease and the liver: A review
- MBOAT7 in liver and extrahepatic diseases